942487-16-3 Usage
Description
PF-03814735 is a reversible inhibitor of Aurora A and B kinases, which are key regulators of mitosis and cytokinesis. It also inhibits other kinases such as FLT1, FAK, TrkA, Met, and FGFR1. PF-03814735 has demonstrated in vitro and in vivo efficacy against various tumor cell lines, particularly small cell lung cancer and tumors driven by the Myc family genes.
Uses
Used in Cancer Therapy:
PF-03814735 is used as an anticancer agent for cancer therapy. It inhibits the growth of various tumor cell lines, including HCT116, HL-60, A549, and H125, with IC50 values ranging from 42-150 nM. It has shown particular sensitivity towards small cell lung cancer cell lines and other tumors driven by the Myc family genes.
Used in Drug Development:
PF-03814735 is an orally bioavailable small molecule aurora kinase inhibitor that plays a key role in the regulation of mitosis. It is used in drug development for the treatment of various types of cancer, particularly those driven by the Aurora kinases and other targeted kinases.
references
[1] jani jp, arcari j, bernardo v, bhattacharya sk, briere d, cohen bd, coleman k, christensen jg, emerson eo, jakowski a, hook k, los g, moyer jd, pruimboom-brees i, pustilnik l, rossi am, steyn sj, su c, tsaparikos k, wishka d, yoon k, jakubczak jl. pf-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. mol cancer ther. 2010 apr;9(4):883-94.
Check Digit Verification of cas no
The CAS Registry Mumber 942487-16-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,2,4,8 and 7 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 942487-16:
(8*9)+(7*4)+(6*2)+(5*4)+(4*8)+(3*7)+(2*1)+(1*6)=193
193 % 10 = 3
So 942487-16-3 is a valid CAS Registry Number.
942487-16-3Relevant articles and documents
PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
-
Page/Page column 102, (2010/11/27)
The present invention relates to a compound of the formula (I), or a pharmaceutically acceptable salt thereof, wherein Ar is a group of formula (III), and R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, salt thereof, wherein R1, R2, R13, A, K, L1, L2, W, X, Z1, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p and q are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
